MN-SITEIMPROVE
17.1.2023 15:01:38 CET | Business Wire | Press release
Siteimprove, the leading platform that empowers brands to stand out with engaging, accessible, and high-performing digital content experiences, today announced key appointments to its growing executive leadership team. These hires are designed to strengthen the company’s focus on growth, innovation, and customer success. Iza Misiorny is taking on the position of Chief Marketing Officer and Elliott DeLoach is now the company’s Chief Financial Officer.
In her new role, Misiorny will lead the global marketing team focused on driving brand awareness, product positioning and demand generation for Siteimprove’s state of the art marketing solutions worldwide. Misiorny has more than a decade of experience and has been with Siteimprove for more than two years. Most recently, she served as the company’s Senior Vice President of Product Marketing, where she developed and drove product value proposition, company messaging, and integrated marketing strategies.
Elliott DeLoach was hired in December as Chief Financial Officer. He will be overseeing Siteimprove’s finance, legal, and corporate governance functions to drive the company’s next phase of growth. DeLoach brings more than 25 years of experience in investment, M&A, finance, and corporate development roles, spanning banking, private equity, and both private and public companies across many industries.
In addition to the appointment of Misiorny and DeLoach, Siteimprove is also expanding its commercial leadership team. Eric Gorney has been named Siteimprove’s Executive Vice President of Global Sales, where he will drive global sales strategy, execution, and full life-cycle engagement across EMEA, North America, and APJ regions. To continue efficiently growing sales operations, Kara Kovack has been promoted to Senior Vice President of Commercial Operations. She will provide operational support, enablement, and education for the company across the full Go-To-Market motion. With this combination of experienced and results-oriented commercial leaders, Siteimprove will continue to rapidly accelerate its scale and growth.
“One of the most rewarding parts of my job is bringing incredible talent to Siteimprove and watching that talent grow and flourish,” said Shane Paladin, CEO of Siteimprove. “I’m thrilled to welcome Elliott to the leadership team and excited to see what more Iza, Eric and Kara will accomplish in their elevated roles. With a world-class executive bench now in place, Siteimprove is uniquely positioned to help more brands capture consumer attention by building content that turns a profit.”
See more on Siteimprove’s full leadership team here.
About Siteimprove:
Siteimprove empowers brands to stand out with engaging, accessible, and high-performing digital experiences for every website visitor. More than 7,000 companies around the world use Siteimprove solutions to create engaging digital content experiences that capture customer attention, drive marketing success, and grow revenue. See how at Siteimprove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005116/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
